Crinetics Pharmaceuticals, Inc. financial data

Symbol
CRNX on Nasdaq
Location
San Diego, CA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 26 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1642% % -11%
Debt-to-equity 11% % -1.5%
Return On Equity -41% % -34%
Return On Assets -37% % -34%
Operating Margin -6715% % 79%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 104,705,330 shares
Common Stock, Shares, Outstanding 95,575,000 shares 2.9%
Entity Public Float $2,700,000,000 USD -23%
Common Stock, Value, Issued $881,000 USD
Weighted Average Number of Shares Outstanding, Basic 94,057,000 shares 16%
Weighted Average Number of Shares Outstanding, Diluted 94,057,000 shares 16%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $1,031,000 USD 158%
Revenue from Contract with Customer, Excluding Assessed Tax $7,696,000 USD 641%
Research and Development Expense $332,058,000 USD 38%
General and Administrative Expense $165,812,000 USD 87%
Operating Income (Loss) $516,769,000 USD -53%
Nonoperating Income (Expense) $51,632,000 USD 26%
Net Income (Loss) Attributable to Parent $465,317,000 USD -56%
Earnings Per Share, Basic -4.95 USD/shares -34%
Earnings Per Share, Diluted -4.95 USD/shares -34%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $101,536,000 USD -62%
Cash, Cash Equivalents, and Short-term Investments $1,000,000,000 USD -29%
Accounts Receivable, after Allowance for Credit Loss, Current $592,000 USD
Inventory, Net $2,022,000 USD
Other Assets, Current $3,456,000 USD 44%
Assets, Current $1,048,342,000 USD -24%
Property, Plant and Equipment, Net $14,296,000 USD 18%
Operating Lease, Right-of-Use Asset $40,492,000 USD -6.9%
Other Assets, Noncurrent $14,150,000 USD 608%
Assets $1,126,257,000 USD -21%
Accounts Payable, Current $22,611,000 USD 286%
Contract with Customer, Liability, Current $1,235,000 USD -43%
Liabilities, Current $85,072,000 USD 43%
Contract with Customer, Liability, Noncurrent $3,810,000 USD -19%
Operating Lease, Liability, Noncurrent $42,052,000 USD -5.6%
Other Liabilities, Noncurrent $3,240,000 USD 291%
Liabilities $134,174,000 USD 22%
Common Stocks, Including Additional Paid in Capital $2,407,757,000 USD 5.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax $1,865,000 USD 94%
Retained Earnings (Accumulated Deficit) $1,417,427,000 USD -49%
Stockholders' Equity Attributable to Parent $992,083,000 USD -25%
Liabilities and Equity $1,126,257,000 USD -21%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $88,452,000 USD -67%
Net Cash Provided by (Used in) Financing Activities $4,437,000 USD -99%
Net Cash Provided by (Used in) Investing Activities $85,961,000 USD -27919%
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 95,575,000 shares 2.9%
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $169,976,000 USD -150%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $102,336,000 USD -62%
Deferred Tax Assets, Valuation Allowance $392,031,000 USD 39%
Deferred Tax Assets, Gross $401,271,000 USD 38%
Operating Lease, Liability $48,541,000 USD -6.2%
Payments to Acquire Property, Plant, and Equipment $1,239,000 USD -7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $464,415,000 USD -56%
Lessee, Operating Lease, Liability, to be Paid $71,979,000 USD -9.4%
Property, Plant and Equipment, Gross $22,248,000 USD 12%
Operating Lease, Liability, Current $6,489,000 USD -9.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two $6,999,000 USD 3%
Lessee, Operating Lease, Liability, to be Paid, Year One $6,795,000 USD -9%
Operating Lease, Weighted Average Discount Rate, Percent 0.086 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $23,438,000 USD -15%
Lessee, Operating Lease, Liability, to be Paid, Year Three $7,209,000 USD 3%
Deferred Tax Assets, Operating Loss Carryforwards $201,110,000 USD 84%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $14,752,000 USD 38%
Lessee, Operating Lease, Liability, to be Paid, Year Four $7,425,000 USD 3%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $9,240,000 USD -5.2%
Share-based Payment Arrangement, Expense $91,024,000 USD 31%
Preferred Stock, Par or Stated Value Per Share 0.001 USD/shares 0%